Supernus Pharma’s ADHD treatment succeeds in two late-stage studies

(Reuters) – Supernus Pharmaceuticals Inc on Thursday said its experimental treatment for attention deficit hyperactivity disorder (ADHD) met the main goal of reducing disorder symptoms in children in two late-stage studies.

The treatment, SPN-812, was being tested in children aged six to 11 years diagnosed with ADHD.

The company expects to submit a marketing application for SPN-812 in the second half of 2019, and to launch it, pending U.S. Food and Drug Administration approval, in the second half of 2020.

Reporting by Manogna Maddipatla in Bengaluru; Editing by Bernard Orr

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *